Localization of Phosphorylated ERK/MAP Kinases to Mitochondria and Autophagosomes in Lewy Body Diseases

Overview

Journal Brain Pathol

Date 2003 Dec 6

PMID 14655753

Citations 133

Authors

Jian-Hui Zhu

Fengli Guo

John Shelburne

Simon Watkins

Charleen T Chu

Affiliations

Soon will be listed here.

Abstract

We previously found that sustained ERK activation contributes to toxicity elicited by the parkinsonian neurotoxin 6-hydroxydopamine. In addition, substantia nigra neurons from patients with incidental Lewy body disease, Parkinson disease (PD), and diffuse Lewy body dementia (DLB) display abnormal phospho-ERK accumulations in the form of discrete cytoplasmic granules. In this study, we investigated the subcellular localization of phospho-ERK immunoreactive granules using double label confocal microscopy and immuno-electron microscopy. A small percentage of phospho-ERK granules co-localized with the early endosome marker Rab5, but not with cathepsin D, 20S proteasome beta-subunit, or cytochrome P450 reductase. Phospho-ERK immunoreactivity was often associated with mitochondrial proteins (MnSOD, 60 kDa and 110 kDa mitochondrial antigens), and some vesicular-appearing phospho-ERK granules appeared to envelop enlarged mitochondria by confocal laser scanning microscopy. Ultrastructural immuno-gold studies revealed phospho-ERK labeling in mitochondria and in association with bundles of approximately 10 nm fibrils. Heavily labeled mitochondria were observed within autophagosomes. As mitochondrial pathology may play a pivotal role in Parkinson and other related neurodegenerative diseases, these studies suggest a potential interaction between dysfunctional mitochondria, autophagy, and ERK signaling pathways.

Citing Articles

Mitophagy-associated programmed neuronal death and neuroinflammation.

Zhu Y, Zhang J, Deng Q, Chen X Front Immunol. 2024; 15:1460286.

PMID: 39416788 PMC: 11479883. DOI: 10.3389/fimmu.2024.1460286.

Neuronal regulated cell death in aging-related neurodegenerative diseases: key pathways and therapeutic potentials.

Song R, Yin S, Wu J, Yan J Neural Regen Res. 2024; 20(8):2245-2263.

PMID: 39104166 PMC: 11759035. DOI: 10.4103/NRR.NRR-D-24-00025.

Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.

Hussain M, Moglad E, Afzal M, Sharma S, Gupta G, Sivaprasad G CNS Neurosci Ther. 2024; 30(5):e14763.

PMID: 38790149 PMC: 11126788. DOI: 10.1111/cns.14763.

Pharmacological Inhibition of LRRK2 Exhibits Neuroprotective Activity in Mouse Photothrombotic Stroke Model.

Hwang J, Choi S, Kim S, Kim D Exp Neurobiol. 2024; 33(1):36-45.

PMID: 38471803 PMC: 10938073. DOI: 10.5607/en23023.

The interplay of mitophagy, autophagy, and apoptosis in cisplatin-induced kidney injury: involvement of ERK signaling pathway.

Suman I, Simic L, canadi Juresic G, Buljevic S, Klepac D, Domitrovic R Cell Death Discov. 2024; 10(1):98.

PMID: 38402208 PMC: 10894217. DOI: 10.1038/s41420-024-01872-0.

References

Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G . Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem. 2000; 275(16):12200-6. DOI: 10.1074/jbc.275.16.12200. View

Bonni A, Brunet A, West A, Datta S, Takasu M, Greenberg M . Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999; 286(5443):1358-62. DOI: 10.1126/science.286.5443.1358. View

Cassarino D, Halvorsen E, Swerdlow R, Abramova N, Parker Jr W, Sturgill T . Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease. J Neurochem. 2000; 74(4):1384-92. DOI: 10.1046/j.1471-4159.2000.0741384.x. View

Chu C, Caruso J, Cummings T, Ervin J, Rosenberg C, Hulette C . Ubiquitin immunochemistry as a diagnostic aid for community pathologists evaluating patients who have dementia. Mod Pathol. 2000; 13(4):420-6. DOI: 10.1038/modpathol.3880072. View

Cha Y, Kim Y, Ahn Y, Koh J . Epidermal growth factor induces oxidative neuronal injury in cortical culture. J Neurochem. 2000; 75(1):298-303. DOI: 10.1046/j.1471-4159.2000.0750298.x. View

Rizzo M, Shome K, Watkins S, Romero G . The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem. 2000; 275(31):23911-8. DOI: 10.1074/jbc.M001553200. View

Duda J, Giasson B, Chen Q, Gur T, Hurtig H, Stern M . Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol. 2000; 157(5):1439-45. PMC: 1885725. DOI: 10.1016/S0002-9440(10)64781-5. View

Klionsky D, Emr S . Autophagy as a regulated pathway of cellular degradation. Science. 2000; 290(5497):1717-21. PMC: 2732363. DOI: 10.1126/science.290.5497.1717. View

Ogier-Denis E, Pattingre S, El Benna J, Codogno P . Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. J Biol Chem. 2000; 275(50):39090-5. DOI: 10.1074/jbc.M006198200. View

10.

McNaught K, Jenner P . Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett. 2001; 297(3):191-4. DOI: 10.1016/s0304-3940(00)01701-8. View

11.

Galvin J, Lee V, Trojanowski J . Synucleinopathies: clinical and pathological implications. Arch Neurol. 2001; 58(2):186-90. DOI: 10.1001/archneur.58.2.186. View

12.

Pearson G, Robinson F, Beers Gibson T, Xu B, Karandikar M, Berman K . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22(2):153-83. DOI: 10.1210/edrv.22.2.0428. View

13.

Kulich S, Chu C . Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem. 2001; 77(4):1058-66. PMC: 1868550. DOI: 10.1046/j.1471-4159.2001.00304.x. View

14.

Goedert M . Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001; 2(7):492-501. DOI: 10.1038/35081564. View

15.

Dickson D . Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol. 2001; 14(4):423-32. DOI: 10.1097/00019052-200108000-00001. View

16.

McNaught K, Olanow C, Halliwell B, Isacson O, Jenner P . Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001; 2(8):589-94. DOI: 10.1038/35086067. View

17.

Rideout H, Larsen K, Sulzer D, Stefanis L . Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem. 2001; 78(4):899-908. DOI: 10.1046/j.1471-4159.2001.00474.x. View

18.

Xia X, Harding T, Weller M, Bieneman A, Uney J, Schulz J . Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(18):10433-8. PMC: 56978. DOI: 10.1073/pnas.181182298. View

19.

Bursch W . The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ. 2001; 8(6):569-81. DOI: 10.1038/sj.cdd.4400852. View

20.

Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K . Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001; 98(20):11569-74. PMC: 58770. DOI: 10.1073/pnas.181213498. View